Abstract
Introduction:Chemotherapy-induced nausea and vomiting (CINV) is one of the scariest chemotherapy-induced adverse effects. We evaluated the adherence to the 2017 American Society of Clinical Oncology (ASCO), the latest guideline recommendations, for the management of acute CINV at our institute. Methods:During a 6-months cross-sectional study on outpatient’s cancer patients, we collected data from the prescription documents during temporary hospitalization and compared the results with ASCO guideline recommendations. Results:The most prescribed prophylactic regimens for the management of CINV were combination of aprepitant, granisetron, and dexamethasone and metoclopramide (51.8%). Regarding prescription compatibility in our center with ASCO guideline recommnedations, selection of different regimens for prophylaxis of acute CINV in our institute was compliant in 0 %, 22%, 4%, and 40% of high, moderate, low, and minimal emetogenic potential of chemotherapy regimen groupss, respectively. Conclusion:Although our hospital is a referral and university-affiliated center, adherence to the ASCO guideline recommendations for prophylaxis of CINV was poor.
Highlights
Chemotherapy-induced nausea and vomiting (CINV) is one of the scariest chemotherapy-induced adverse effects
We evaluated the adherence to the 2017 American Society of Clinical Oncology (ASCO), the latest guideline recommendations, for the management of acute CINV at our institute
Our study revealed that the adherence to the ASCO 2017 clinical recommendations (Hesketh et al, 2017) for prophylaxis of CINV at our institute was not optimal
Summary
Chemotherapy-induced nausea and vomiting (CINV) is one of the scariest chemotherapy-induced adverse effects. We evaluated the adherence to the 2017 American Society of Clinical Oncology (ASCO), the latest guideline recommendations, for the management of acute CINV at our institute. Up to 80% of patients receiving chemotherapy experience CINV, leading to complications, such as electrolyte imbalances, dehydration, malnutrition, and quality of life deterioration (Koth and Kolesar, 2017). Several medications, such as corticosteroids, serotonin and neurokinin antagonists, dopamine antagonists, and benzodiazepines have been used for the management of CINV. The American Society of Clinical Oncology (ASCO) recommendations are the basis for medical oncology issues, such as CINV management, and are updated periodically according to scientific and new evidence (Hesketh et al, 2017)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
